Role of HDL phospholipid in efflux of cell cholesterol to whole serum: studies with human apoA-I transgenic rats.
Sera of transgenic rats expressing human apoA-I were tested for their ability to stimulate efflux of radiolabeled cholesterol from Fu5AH rat hepatoma cells. Expression of human apoA-I resulted in a dose-dependent increase in HDL, as measured by both HDL-cholesterol and HDL-phospholipid, and produced a decrease in rat apoA-I. In rats expressing high concentrations of human apoA-I (TgR[hAI]high, human apoA-I > 250 mg/dl), the increase in HDL-phospholipid was not proportional to the increase in human apoA-I, as illustrated by a HDL-PL/total apoA-I ratio of 0.84 +/- 0.19 compared to a ratio of 1.28 +/- 0.29 for control rats and of 1.28 +/- 0.39 for rats expressing low levels of human apoA-I (TgR[hAI]low, human apoA-I < 250 mg/dl). Compared to sera from control animals, efflux of cell cholesterol was increased by 26% in the sera from TgR[hAI]low, and by 76% in the TgR[hAI]high. An examination of the relationships between efflux and HDL-related parameters demonstrated a hyperbolic relationship between efflux and either HDL-cholesterol or HDL-apoA-I. In contrast, there was a strong linear association (r2 = 0.84) between cholesterol efflux and HDL-phospholipid, indicating that this parameter is the component of HDL that best reflects the serum's efflux efficiency. The importance of phospholipids in modulating cholesterol efflux was further explored by measuring the effect of supplementation of serum with dimyristoylphosphatidylcholine (DMPC) vesicles, apoA-I, or both DMPC vesicles and apoA-I. Whereas addition of human apoA-I had no effect on efflux, supplementation with DMPC vesicles produced a substantial increase in efflux that was further stimulated by the combination of DMPC vesicles and apoA-I. These results demonstrate that a major component of HDL that modulates cell cholesterol efflux is phospholipid.
Fournier
N
N
Hospital Broussais Paris, France.
de la Llera Moya
M
M
Burkey
B F
BF
Swaney
J B
JB
Paterniti
J
J
Moatti
N
N
Atger
V
V
Rothblat
G H
GH
D000818:Animals; D030801:Animals, Genetically Modified; D016632:Apolipoprotein A-I / Q000096:biosynthesis / Q000097:blood / Q000235:genetics / Q000378:metabolism; D001692:Biological Transport; D008076:Cholesterol, HDL / Q000378:metabolism*; D004134:Dimyristoylphosphatidylcholine / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay; D005089:Exocytosis; D005260:Female; D006801:Humans; D007202:Indicators and Reagents / Q000494:pharmacology; D008099:Liver / Q000737:chemistry / Q000166:cytology / Q000378:metabolism*; D008297:Male; D010743:Phospholipids / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism; D019076:Transgenes / Q000235:genetics*
D016632:Apolipoprotein A-I; D008076:Cholesterol, HDL; D007202:Indicators and Reagents; D010743:Phospholipids; D011994:Recombinant Proteins; D004134:Dimyristoylphosphatidylcholine